Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AGIONASDAQ:EWTXNASDAQ:IRONNASDAQ:KIN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGIOAgios Pharmaceuticals$28.34-5.4%$29.60$23.42▼$62.58$1.74B0.77700,115 shs836,971 shsEWTXEdgewise Therapeutics$14.38-13.1%$18.90$10.60▼$38.12$1.51B0.361.16 million shs1.40 million shsIRONDisc Medicine$42.71-12.1%$47.60$28.25▼$68.73$1.48B0.77346,943 shs800,676 shsKINKindred Biosciences$9.25$9.22$3.46▼$9.28$420.52M1.3840,890 shs178,496 shs20 Stocks to Sell NowGet This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGIOAgios Pharmaceuticals-0.43%+1.18%+16.34%-11.88%-13.23%EWTXEdgewise Therapeutics-2.19%+5.48%+43.70%-43.93%-15.27%IRONDisc Medicine-1.84%+5.29%+17.90%-10.53%+63.14%KINKindred Biosciences0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAGIOAgios Pharmaceuticals4.1858 of 5 stars3.32.00.04.23.10.81.9EWTXEdgewise Therapeutics3.0569 of 5 stars4.41.00.00.03.53.30.0IRONDisc Medicine2.281 of 5 stars3.51.00.00.04.02.50.0KINKindred BiosciencesN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGIOAgios Pharmaceuticals 2.56Moderate Buy$56.0097.60% UpsideEWTXEdgewise Therapeutics 2.78Moderate Buy$40.22179.81% UpsideIRONDisc Medicine 3.09Buy$93.80119.61% UpsideKINKindred Biosciences 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest KIN, AGIO, IRON, and EWTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/2/2025AGIOAgios PharmaceuticalsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Outperform ➝ Sector Outperform$74.00 ➝ $71.004/30/2025EWTXEdgewise TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$41.004/21/2025EWTXEdgewise TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$43.00 ➝ $43.004/3/2025EWTXEdgewise TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$56.00 ➝ $52.004/2/2025EWTXEdgewise TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$51.00 ➝ $51.004/2/2025EWTXEdgewise TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeSector Outperform ➝ Sector Perform$50.00 ➝ $14.003/18/2025IRONDisc MedicineCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$99.00 ➝ $132.003/7/2025EWTXEdgewise TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSector Outperform$50.003/7/2025IRONDisc MedicineMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight$85.003/4/2025EWTXEdgewise TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$56.00 ➝ $56.003/3/2025IRONDisc MedicineScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Outperform ➝ Sector Outperform$73.00 ➝ $75.00(Data available from 5/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGIOAgios Pharmaceuticals$37.04M44.32N/AN/A$27.02 per share1.05EWTXEdgewise TherapeuticsN/AN/AN/AN/A$4.53 per shareN/AIRONDisc MedicineN/AN/AN/AN/A$14.17 per shareN/AKINKindred Biosciences$42.16M9.97N/AN/A$1.75 per share5.29Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGIOAgios Pharmaceuticals$673.72M$11.242.50N/AN/A1,845.92%-2.51%-2.26%N/AEWTXEdgewise Therapeutics-$100.16M-$1.45N/AN/AN/AN/A-26.83%-25.67%5/8/2025 (Estimated)IRONDisc Medicine-$76.43M-$3.99N/AN/AN/AN/A-25.24%-23.96%5/8/2025 (Estimated)KINKindred Biosciences-$21.80M-$0.55N/AN/AN/A-529.26%-54.19%-39.76%N/ALatest KIN, AGIO, IRON, and EWTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025EWTXEdgewise Therapeutics-$0.45N/AN/AN/AN/AN/A5/8/2025Q1 2025IRONDisc Medicine-$0.99N/AN/AN/AN/AN/A5/1/2025Q1 2025AGIOAgios Pharmaceuticals-$1.80-$1.55+$0.25-$1.55$9.86 million$8.73 million3/3/2025Q4 2024EWTXEdgewise Therapeutics-$0.39-$0.42-$0.03-$0.42N/AN/A2/27/2025Q4 2024IRONDisc Medicine-$1.06-$0.98+$0.08-$0.98N/AN/A2/20/2025Q4 2024AGIOAgios Pharmaceuticals-$1.69-$1.74-$0.05-$1.74$9.35 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAGIOAgios PharmaceuticalsN/AN/AN/AN/AN/AEWTXEdgewise TherapeuticsN/AN/AN/AN/AN/AIRONDisc MedicineN/AN/AN/AN/AN/AKINKindred BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGIOAgios PharmaceuticalsN/A11.9011.56EWTXEdgewise TherapeuticsN/A26.3526.35IRONDisc MedicineN/A19.3619.36KINKindred Biosciences0.197.027.02Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGIOAgios PharmaceuticalsN/AEWTXEdgewise TherapeuticsN/AIRONDisc Medicine83.70%KINKindred Biosciences66.89%Insider OwnershipCompanyInsider OwnershipAGIOAgios Pharmaceuticals4.93%EWTXEdgewise Therapeutics24.11%IRONDisc Medicine4.24%KINKindred Biosciences13.69%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAGIOAgios Pharmaceuticals39057.92 million54.47 millionOptionableEWTXEdgewise Therapeutics60104.77 million71.86 millionOptionableIRONDisc Medicine3034.57 million28.50 millionNot OptionableKINKindred Biosciences6345.46 millionN/AOptionableKIN, AGIO, IRON, and EWTX HeadlinesRecent News About These CompaniesErnest MarioOctober 24, 2024 | centraljersey.comDuke Flags Lowered: Ernest Mario, Founding Chair of DUHS Board of Directors, DiesOctober 23, 2024 | today.duke.eduWhy Silicon Valley falls prey to ‘charisma distortion,’ according to investor and Google X founding member Tom ChiAugust 19, 2024 | msn.comWillow Smith announces the new release date of her first book “Black Shields Maiden”April 23, 2024 | msn.comExplosive Growth Projected in US Pet Medication Market, the Industry to Reach $17.90 Billion by 2029 - Exclusive Focus Insight Report by AriztonApril 2, 2024 | prnewswire.co.ukTory party donor Frank Hester to be investigated for 'racist comments' by West Yorkshire PoliceMarch 22, 2024 | mirror.co.ukNagaland Assembly passes resolution against Centre’s move to fence India-Myanmar borderMarch 2, 2024 | scroll.inKindred Hospital East GreensboroFebruary 23, 2024 | health.usnews.comJapan's Sony terminates $10 bln Zee India mergerJanuary 22, 2024 | reuters.comEuropean Shares Edge Higher With ECB Meeting In The SpotlightJanuary 22, 2024 | markets.businessinsider.comEarnings Optimism May Contribute To Continued Strength On Wall StreetJanuary 22, 2024 | markets.businessinsider.comAuthorities investigating garage fire in KindredDecember 28, 2023 | valleynewslive.comHonoree: Nanxi LiuDecember 17, 2023 | latimes.comStart-up Cradle tucks in $24m for protein engineering AINovember 29, 2023 | pharmaphorum.comStartup Cradle tucks in $24m for protein engineering AINovember 29, 2023 | pharmaphorum.comGlobal Companion Animal Pharmaceuticals Market Size To Worth USD 27.16 Billion by 2032 | CAGR of 5.7%November 8, 2023 | finance.yahoo.comMizoram Assembly elections: Incumbent MNF faces tough challenge; a look at key candidates and constituenciesNovember 6, 2023 | devdiscourse.comMat-Su Assembly member agrees to pay $77,500 for extending property into lake and wetlandsOctober 8, 2023 | adn.comKindred Hospital-DaytonOctober 7, 2023 | health.usnews.comBluejay Therapeutics expands management team and hired Christopher Holterhoff as senior Vice President, head of business developmentSeptember 21, 2023 | tmcnet.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines4 Dividend Growth Stocks the Trade Tariffs Can’t TouchBy Thomas Hughes | April 7, 2025View 4 Dividend Growth Stocks the Trade Tariffs Can’t TouchQuantum Computing: The $6.5 Billion Opportunity You Can’t IgnoreBy Jeffrey Neal Johnson | April 9, 2025View Quantum Computing: The $6.5 Billion Opportunity You Can’t IgnoreViking Therapeutics Stock Pops But Struggles to Hold GainsBy Chris Markoch | April 16, 2025View Viking Therapeutics Stock Pops But Struggles to Hold GainsOil Prices Are Tanking—These 3 Plays Could Fuel Your GainsBy Gabriel Osorio-Mazilli | April 9, 2025View Oil Prices Are Tanking—These 3 Plays Could Fuel Your Gains3 Dividend Kings Outshining the Market in 2025By Ryan Hasson | April 30, 2025View 3 Dividend Kings Outshining the Market in 2025KIN, AGIO, IRON, and EWTX Company DescriptionsAgios Pharmaceuticals NASDAQ:AGIO$28.34 -1.63 (-5.44%) Closing price 03:59 PM EasternExtended Trading$28.32 -0.02 (-0.05%) As of 06:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.Edgewise Therapeutics NASDAQ:EWTX$14.38 -2.17 (-13.09%) Closing price 03:59 PM EasternExtended Trading$14.11 -0.27 (-1.84%) As of 07:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.Disc Medicine NASDAQ:IRON$42.71 -5.89 (-12.12%) Closing price 03:59 PM EasternExtended Trading$42.57 -0.14 (-0.33%) As of 04:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.Kindred Biosciences NASDAQ:KINKindred Biosciences, Inc. is a development-stage biopharmaceutical company, which focuses on saving and improving the lives of pets. The company was founded by Richard Chin and Denise M. Bevers on September 25, 2012 and is headquartered in Burlingame, CA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Top-Ranked Insider Buys From April by Market Cap Palantir Stock Drops Despite Stellar Earnings: What's Next? Hims & Hers Stock Rises on Fundamentals and Squeeze Potential Is Eli Lilly a Buy After Weak Earnings and CVS-Novo Partnership? D-Wave Quantum: Hidden Opportunity or Short Seller's Dream? Microsoft Stock After Xbox Price Hike: Buy or Hold? Uncertainty Creates Opportunity for Tyson Foods Investors Why Wells Fargo Is Buying $40 Billion of Its Own Stock Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
